Is there any benefit of preoperative oral trimetazidine in coronary artery bypass graft?

Journal of the Pakistan Medical Association

Volumn 62, Issue 12, 2012, Pages 1271-1276

  Sher i Murtaza, Muhammad ^a   Zubair, Muhammad ^a   Jalal, Anjum ^a  

^a CPE Institute of Cardiology   (Pakistan)

Author keywords

CABG; Myocardial protection; Trimetazidine

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; HEPARIN; TRIMETAZIDINE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; CREATINE KINASE; CREATINE KINASE, MB FORM; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAKISTAN; PLACEBOS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84870317777     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Okabe E, Fujimaki R, Murayama M, Ito H. Possible mechanism responsible for mechanical dysfunction of ischemic myocardium: a role of oxygen free radicals. Jpn Circ J 1989; 53: 1132-7.
2. Bolli R, Jeroudi MO, Patel BS, Aruoma OI, Halliwell B, Lai EK, et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial stunning is a manifestation of reperfusion injury. Circ Res 1989; 65: 607-22.
3. Desideri A, Celegon L. Metabolic management of ischemic heart disease: clinical data with trimetazidine. Am J Cardiol 1998; 82: 50K-3K.
4. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279-88.
5. Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97-110.
6. Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828-33.
7. Stanley WC. Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy. European Heart J Supp 2001; 3(Suppl O): O2-O7.
8. Stanley WC. Cardiac energetics during ischaemia and the rationale for metabolic interventions. Coron Artery Dis 2001; 12 Suppl 1: S3-7
9. Knight C, Fox K. From antianginal drugs to myocardial cytoprotective agents. Am J Cardiol 1995; 76: 4B-7B.
10. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003; 93: 292-301.
11. Dennis SC, Gevers W, Opie LH. Protons in ischemia: where do they come from; where do they go to? J Mol Cell Cardiol 1991; 23: 1077-86.
12. Ambrosio G, Zweier JL, Duilio C, Kuppusamy P, Santoro G, Elia PP, et al. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem 1993; 268: 18532-41.
13. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003; 93: e33-7.
14. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
15. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993; 46: 324-31.
16. Pichon G, Rousseau D, Helies C et al. Control by Trimetazidine of the energy substrate balance in ventricular myocite. J Moll Cell Cardiol 1999; 31: A88.
17. Tritto I, Wang P, Kuppusamy P, Giraldez R, Zweier JL, Ambrosio G. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol 2005; 46: 89-98.
18. Effect of 48-h intravenous trimetazidine on short and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP FR Group. European Myocardial Infarction Project--Free Radicals. Eur Heart J 2000; 21: 1537-46.
19. Tunerir B, Colak O, Alatas O, Besogul Y, Kural T, Aslan R. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999; 68: 2173-6.
20. Iskesen I, Kurdal AT, Eserdag M, Cerrahoglu M, Sirin BH. Trimetazidine may protect the myocardium during cardiac surgery. Heart Surg Forum 2009; 12: E175-9.
21. Vedrinne JM, Vedrinne C, Bompard D, Lehot JJ, Boissel JP, Champsaur G. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 1996; 82: 712-8.